← Back to Screener
Silexion Therapeutics Corp Ordinary Shares (SLXN)
Price$1.08
Favorite Metrics
Price vs S&P 500 (26W)-81.13%
Price vs S&P 500 (4W)-21.79%
Market Capitalization$3.63M
All Metrics
Book Value / Share (Quarterly)$0.83
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.46
Price vs S&P 500 (YTD)-48.41%
EPS (TTM)$-12.44
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$-12.44
EPS (Annual)$-8.96
ROI (Annual)-285.59%
Cash / Share (Quarterly)$1.92
ROA (Last FY)-165.10%
EBITD / Share (TTM)$-8.76
Cash Flow / Share (Annual)$-3.46
P/B Ratio1.40x
P/B Ratio (Quarterly)2.31x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-44.11x
ROA (TTM)-144.68%
EPS Incl Extra (Annual)$-8.96
Current Ratio (Annual)2.41x
Quick Ratio (Quarterly)2.20x
3-Month Avg Trading Volume0.05M
52-Week Price Return-90.75%
Revenue / Employee (TTM)$0
52-Week High$22.36
EPS Excl Extra (Annual)$-8.96
26-Week Price Return-72.39%
Quick Ratio (Annual)2.20x
13-Week Price Return-49.53%
Total Debt / Equity (Annual)0.60x
Current Ratio (Quarterly)2.41x
Enterprise Value$-0.791
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.92
3-Month Return Std Dev92.44%
Net Income / Employee (TTM)$-1
ROE (Last FY)-457.63%
EPS Basic Excl Extra (Annual)$-8.96
Total Debt / Equity (Quarterly)0.60x
EPS Incl Extra (TTM)$-12.44
ROI (TTM)-220.83%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-125.85%
Year-to-Date Return-44.27%
5-Day Price Return8.06%
EPS Normalized (Annual)$-8.96
ROA (5Y Avg)-167.88%
Month-to-Date Return-16.41%
EBITD / Share (Annual)$-8.75
LT Debt / Equity (Annual)0.60x
LT Debt / Equity (Quarterly)0.60x
EPS Basic Excl Extra (TTM)$-12.44
P/B Ratio (Annual)2.31x
Book Value / Share (Annual)$0.83
Price vs S&P 500 (13W)-52.39%
Beta0.02x
P/FCF (Annual)4.43x
Revenue / Share (TTM)$0.00
ROE (TTM)-387.82%
52-Week Low$0.97
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SLXNSilexion Therapeutics Corp Ordinary Shares | — | — | — | — | $1.08 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Silexion Therapeutics is a clinical-stage biotechnology company developing targeted treatments for KRAS-driven cancers. Its lead product candidate, SIL204, is a locally administered siRNA designed to treat locally advanced pancreatic cancer in combination with standard chemotherapy, specifically targeting tumors with KRAS G12D and G12V mutations. The company focuses on non-resectable cases where surgical removal is not possible.